Eli Lilly & Co. will immediately make Retevmo (selpercatinib) available to patients after securing US Food and Drug Administration approval on 8 May for the RET inhibitor in certain cancers driven by rearranged during transfusion (RET) alterations. Lilly Oncology president Anne White said in an interview that given the critical nature of the treatment, the company will launch the drug immediately despite the challenging commercial dynamics caused by the COVID-19 pandemic.
Lilly Moves Ahead With Retevmo Launch In A Challenging Environment
The company secured FDA approval for selpercatinib in RET-driven NSCLC and thyroid cancer, months ahead of the PDUFA date. Oncology president Anne White talked to Scrip about the launch.
More from New Products
More from Scrip
• By
The company reported positive topline results for ASCENT-04, which also bode well for the ASCENT-03 trial in patients with low PD-L1 expression.
• By
Merck’s immuno-oncology blockbuster was the world’s best-selling drugs by revenues for the second year in a row, with an almost $12bn lead over its closest rival, Novo Nordisk’s GLP-1 drug Ozempic.
• By
AstraZeneca and Daiichi’s DESTINY-Breast09 trial testing Enhertu with pertuzumab versus standard of care showed a statistically significant and meaningful PFS improvement.